Veloxis Patent-Cliff Exposure & CMS Drug Spending Portfolio
Veloxis (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $64.0M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $64.0M |
| 2024 Medicare Part D Spend | $16.9M |
| 2024 Medicaid Spend | $47.2M |
| California HCAI SB 17 Filings | 18 WAC filings (max 20.0% 2-yr change) |